BioSpace News Archive

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced positive top-line results for its Phase 3 VANISH-303 study investigating the safety and efficacy of oral ibrexafungerp as a treatment for women with vulvovaginal candidiasis (VVC).

Largest distributor of ophthalmic products in the Midwest to expand Leica Microsystems’ ability to serve strategic accounts and accelerate growth

VistaGen Therapeutics, a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system diseases and disorders with high unmet need, announced financial results for its fiscal year 2020 second quarter ended September 30, 2019.

AmerisourceBergen Corporation reported that in its fiscal year 2019 fourth quarter ended September 30, 2019, revenue increased 5.4 percent to $45.6 billion.

Phase 3 URIROX-1 Trial Achieves Primary Endpoint with Statistically Significant Reduction in Urinary Oxalate in Patients with Enteric Hyperoxaluria

Protalix BioTherapeutics, Inc. announced its third quarter 2019 financial results and provided a corporate update.

GAAP(1) operating loss was $5.3 billion and included a $5.6 billion accrual related to opioid litigation, non-GAAP operating earnings increased 6 percent to $577 million

Kamada Ltd. announced that it will release financial results for the third quarter and nine months ended September 30, 2019, prior to the open of the U.S. financial markets on Wednesday, November 13, 2019.

Oral presentation of Phase III Oral Paclitaxel data at the San Antonio Breast Cancer Symposium

Arch Biopartners Inc., announced that the Phase I human trial of Metablok, the Company’s lead drug candidate for treating organ damage caused by inflammation, has met the primary endpoints of safety and tolerability in the trial’s three single ascending dose cohorts of healthy volunteers.